BioCentury
ARTICLE | Clinical News

Proteon's vonapanitase misses another Phase III

April 5, 2019 8:24 PM UTC

Proteon said vonapanitase missed the co-primary endpoints in the Phase III PATENCY-2 trial to improve vascular access in chronic kidney disease (CKD) patients undergoing surgery for radiocephalic arteriovenous fistula (AVF) creation for hemodialysis.

Compared with placebo, a single dose of vonapanitase failed to significantly improve fistula use for hemodialysis (p=0.328) and secondary patency (p=0.932). The double-blind, North American trial enrolled about 600 patients...

BCIQ Company Profiles

Proteon Therapeutics Inc.